Products Revefenacin was approved in the United States in 2018 as a monodose inhalation solution (Yupelri). The active ingredient belongs to the LAMA group. Structure and properties Revefenacin (C35H43N5O4, Mr = 597.8 g/mol) exists as a white crystalline powder and is sparingly soluble in water. It has an active metabolite formed by hydrolysis. Effects Revefenacin … Revefenacin
Symptoms Possible symptoms of chronic obstructive pulmonary disease (COPD) include a chronic cough, mucus production, sputum, shortness of breath, chest tightness, breath sounds, lack of energy, and sleep disturbances. The symptoms often worsen with physical exertion. An acute worsening of chronic symptoms is referred to as an exacerbation. In addition, numerous systemic and extrapulmonary concomitant … Chronic Obstructive Pulmonary Disease
Products LAMAs are commercially available as powders and inhalation solutions and are administered with a specially designed inhaler or with a nebulizer (nebulizer). LAMA is the acronym for , which means long-acting antagonists at muscarinic receptors. Structure and properties LAMAs are derived from the parasympatholytic atropine, which is a natural plant constituent found in various … LAMA
